Biological E, Canadian firm to manufacture jabs | Latest News India - Hindustan Times
close_game
close_game

Biological E, Canadian firm to manufacture jabs

By, Hindustan Times, New Delhi
Jun 02, 2021 03:34 AM IST

Providence will provide the necessary technology transfer for Biological E to manufacture mRNA vaccines in India, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses

Hyderabad-based Biological E. Limited has tied up with Canada’s Providence Therapeutics to locally manufacture its mRNA coronavirus disease (Covid-19) vaccine, the Hyderabad-based company announced on Tuesday, adding it will run a pivotal trial in India, and seek emergency-use authorisation.

Representational image. (REUTERS)
Representational image. (REUTERS)

“Providence and Biological E announce the execution of a term sheet that sets forth the material terms for a definitive licensing and collaboration agreement and also outlines the terms for sale by Providence of up to 30 million doses of Providence’s proprietary messenger RNA vaccine, PTX-COVID-19-B, to Biological E and other end-buyers,” the companies said in a joint statement.

Hindustan Times - your fastest source for breaking news! Read now.

“This sale represents the sale of all the remaining 2021 Providence production, plus a portion of the early 2022 Providence production, after accounting for the first sale of Providence vaccines to the Province of Manitoba, Canada,” they added.

Also Read | ‘Covishield to be administered in 2 shots, no change in schedule’, says govt

Providence will provide the necessary technology transfer for Biological E to manufacture mRNA vaccines in India, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses. Biological E will be responsible for all clinical development and regulatory activities for the mRNA vaccine in India and other jurisdictions licensed by Biological E.

“This initiative is an important commitment by a Canada-based company to help India and other nations vaccinate their citizens against Covid-19. Providence was founded to serve patients, and this commitment by Biological E allows us to achieve that essential goal,” said Brad Sorenson, chief executive officer of Providence, in a statement.

The financial terms of the transaction, however, have not been disclosed.

“The mRNA platform has emerged as the front runner in delivering the first vaccines for emergency use to combat the Covid-19 pandemic. Biological E. is very pleased to be able to work with Providence on its promising mRNA vaccine candidate. We hope to provide India and other countries yet another option to ramp up their efforts towards achieving herd immunity against Covid-19,” said Mahima Datla, managing director, Biological E Limited.

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Arvind Kejriwal News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
  • ABOUT THE AUTHOR
    author-default-90x90

    Rhythma Kaul works as an assistant editor at Hindustan Times. She covers health and related topics, including ministry of health and family welfare, government of India.

SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, March 28, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On